{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-026112","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2022-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:04:03.839993+00:00","generated_at":"2026-06-25T17:21:13.321035+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emmaus Q1 revenue drops 40% to $3.2M; cash falls to $0.8M; working capital insufficient","bullets":["Net revenue $3.2M, down from $5.3M YoY; sell-through improved but overstocking by distributors hit revenue.","Net loss to common stockholders $1.5M ($0.03/share), improved from $8.4M loss ($0.17/share) in Q1 2021.","Loss from operations widened to $3.1M from $1.6M; operating expenses reduced to $5.3M from $6.5M.","Cash $0.8M at March 31, 2022; management says working capital insufficient for 2022 without additional financing.","Launched Endari telehealth program; Florida Medicaid added Endari to preferred drug list; received UAE marketing authorization."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-026112","json":"https://secwatch.observer/filing/0001213900-22-026112.json","markdown":"https://secwatch.observer/filing/0001213900-22-026112.md","text":"https://secwatch.observer/filing/0001213900-22-026112.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390022026112/0001213900-22-026112-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390022026112/ea159763-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T17:21:13.321035+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}